Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

ANI Pharmaceuticals (ANIP) stock drops as its Iluvien implant fails in a clinical trial versus Eylea marketed by Regeneron ...

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available ...

BAUDETTE, Minn. - ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), a biopharmaceutical company with a market capitalization of $1.25 billion and strong revenue growth of 26.2% over the last twelve months, ...

ATLANTA, June 20, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the ...

Cost regulators for the NHS in England and Wales have again endorsed Alimera Sciences eye implant Iluvien as a treatment for some diabetics with macular oedema. Cost regulators for the NHS in England ...

--Alimera Sciences, Inc., a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that INFARMED, the ...

The National Institute for Health and Care Excellence has issued final guidance recommending Alimera Science's Iluvien (fluocinolone acetonide intravitreal implant) as an option for patients with ...

pSivida (PSDV) has a very important binary event upcoming on October 17, 2013; this is the PDUFA date for Iluvien, an ocular implant for diabetic macular edema that was licensed to Alimera (ALIM ...

pSivida Corp. Announces New ILUVIEN® PDUFA Date of October 17, 2013 WATERTOWN, Mass.--(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV - News), a leader in developing sustained release, drug delivery ...